Overview

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Pharmaceutical Solutions